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Trisomy 13 and 18 are genetic syndromes associated with severe 
systemic anomalies. Despite recent increased survival for these 
infants, little is known about the hepatobiliary complications that 
may arise for them. Direct hyperbilirubinemia (DH) affects 
around 1 in 2,500 (0.04%) of  infants. Although it has not been 
previously documented in the literature, we have clinically 
perceived a high rate of DH in the infants with trisomy 13 and 18 
that we have cared for at Children’s Hospital. 
The goal of this study was to investigate the incidence of DH 
and evaluate structural and biochemical signs that could suggest 
possible underlying etiologies of DH in infants with trisomy 13 
and 18.  
• Retrospective cohort study 
• Inclusion:
• Born between January 1, 2012 and March 1, 2020,
• Diagnosed with trisomy 13 or 18, and
• Admitted to the CHMC or NMC NICUs
• Exclusion:
• Admitted after the first month of life 
• Had fewer than three bilirubin data points recorded
• DH cutoffs of >1 mg/dL as well as >2 mg/dL were used
• Data collected:
• Demographics (sex, GA, race, birth weight, cardiac dx)
• Labs (direct/indirect bilirubin, GGT, AST, ALT)
• Nutrition (TPN type and duration)
• Treatment (ursodiol, phenobarbital)
• Hepatobiliary imaging (ultrasound)
• Analyses between trisomy 13 and 18:
• Descriptive analyses of bilirubin levels
• Continuous variables compared using Fisher’s exact test
• Mann-Whitney U test was used for comparing categorical 
variables 
● Rates of DH were high in patients with trisomy 13 or 18 with a trend 
toward higher rates in trisomy 13 (Table 1) when using the cutoff of 
>1 mg/dL (p=0.503) or >2 mg/dL (p=0.079)
● Indirect and direct bilirubin levels are described in Fig. 1
● There was no association between DH and race (white vs. African 
American, p=0.999), sex (p=0.361), BW (p=0.444), GA (p=0.463). 
● There were higher rates of DH in those infants who received TPN 
compared to no TPN (50.0% vs. 13.3%, p=0.026). 
● Overall rates of DH were still high, however, in those without TPN 
(15% for >2 mg/dL and 20% for >1 mg/dL)
● Of those that presented in the first week, 5/7 (71.4%) had trisomy 
13, and infants with trisomy 13 tended to present earlier than those 
with trisomy 18 (median 5 vs. 12 days, respectively, p=0.097). 
● There was no difference in the rate of abnormal hepatobiliary 
ultrasound between infants with and without DH (p=1.00). 
● DH was more common with Trisomy 13 and 18 patients than what 
has previously been reported for the general population
● This remained true even when excluding those that received TPN
● Clinicians should consider screening all infants with trisomy 13 and 
18 for DH starting in the first week of life and for 4 weeks or until 
cessation of TPN, whichever comes later
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Gestational age at birth (wks) 37 (35, 38) 37 (36, 38)
Birth weight (g) 2620 (2048, 2685) 2040 (1680, 2235)
Male sex 5 (38.5) 4 (18.2)
Race/Ethnicity
White 7 (53.8) 20 (91.0)
African American 5 (38.5) 0 (0.0)
Other 1 (7.7) 1 (4.5)
DH
Defined as >1 mg/dL 7 (53.8) 9 (40.9)
Defined as >2 mg/dL 7 (53.8) 5 (22.7)
Median peak AST 112 (70, 158) 196 (90, 282)
Median peak ALT 32 (29, 122) 75.5 (38, 168)
Median peak GGT 114 (37, 241) 633 (282,1089)
Figure 1. Indirect (A) and direct (B) bilirubin by day of life and direct bilirubin 
stratified by trisomy 13 (C) and 18 (D). The dashed line in B represents the cutoff 
of 1 mg/dL. Each line in C & D represents a single subject’s trend.
Continuous variables described as median (IQR) and categorical as N (%)
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